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Significance of a Multiple Biomarkers Strategy
Including Endothelial Dysfunction to Improve
Risk Stratification for Cardiovascular Events
in Patients at High Risk for Coronary Heart Disease
Toshimitsu Nozaki, MD,* Seigo Sugiyama, MD, PHD,* Hidenobu Koga, MD, PHD,*
Koichi Sugamura, MD,* Keisuke Ohba, MD,* Yasushi Matsuzawa, MD,* Hitoshi Sumida, MD, PHD,†
Kunihiko Matsui, MD, PHD,‡ Hideaki Jinnouchi, MD, PHD,§ Hisao Ogawa, MD, PHD*
Kumamoto, Japan
Objectives We investigated whether a multiple biomarkers strategy that includes plasma levels of endothelium-derived mi-
croparticles (EMP), reflecting endothelial dysfunction, can improve prediction of future cardiovascular events in
patients at high risk for coronary heart disease (CHD).
Background Detailed risk stratification using multiple biomarkers can provide clinical benefits in high-risk patients. Endothe-
lial dysfunction has been described as a predictor of cardiovascular complications.
Methods We measured 3 biomarkers in 488 consecutive patients with various CHD risks: B-type natriuretic peptide (BNP),
high-sensitivity C-reactive protein (hsCRP), and EMP. We followed 387 stable patients at high risk for CHD and
examined future cardiovascular events.
Results During a mean follow-up of 36 months, 55 patients developed cardiovascular events. Multivariate Cox propor-
tional hazards analysis adjusted for established risk factors identified age, BNP, hsCRP, and EMP as significant
and independent predictors of future cardiovascular events (age: hazard ratio [HR]: 1.042, 95% confidence inter-
val [CI]: 1.007 to 1.080, p  0.02; BNP: HR: 1.242, 95% CI: 1.004 to 1.536, p  0.046; hsCRP: HR: 1.468, 95%
CI: 1.150 to 1.875, p  0.002; EMP: HR: 1.345, 95% CI: 1.094 to 1.652, p  0.005). The C statistics for cardio-
vascular events increased when each biomarker or combinations of biomarkers were added to the Framingham
risk model (C statistics: Framingham risk model alone 0.636, Framingham risk  BNP 0.695, Framingham
risk  hsCRP 0.696, Framingham risk  EMP 0.682, and Framingham risk  BNP  hsCRP  EMP 0.763).
Conclusions The assessment of endothelial dysfunction by plasma levels of EMP can independently predict future cardiovas-
cular events in patients at high risk for CHD. A multiple biomarkers strategy that includes endothelial dysfunc-
tion assessed by EMP can identify patients vulnerable to cardiovascular disease. (University Hospital Medical
Information Network number: UMIN000000876) (J Am Coll Cardiol 2009;54:601–8) © 2009 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.05.022o
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ccepted May 25, 2009.pment of cardiovascular events (1). Several biomarkers
ncluding B-type natriuretic peptide (BNP) and high-
ensitivity C-reactive protein (hsCRP) have been reported
o be useful for identifying the high-risk patients, indepen-
ent of the established risk factors, and the multiple
iomarkers strategy has been demonstrated to improve the
isk stratification for cardiovascular events beyond the risk
ssessment based on established risk factors alone (2,3).
iomarkers reflecting different disease pathways may have
he potential advantage of improving predictive power
tility, and improvement of the assessment of cardiovascular
isk with new biomarkers is desirable. It has been demon-
trated that endothelial dysfunction is involved in the
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Multimarkers Strategy With Endothelial Injury August 11, 2009:601–8development of atherothrombo-
genic complications (4) and asso-
ciated with future cardiovascular
events in high-risk patients (5–7);
however, it has not been incor-
porated into the previous multi-
ple biomarkers strategy. Endo-
thelial dysfunction can be clinically
detected by measuring impairment
of endothelium-dependent vaso-
dilatation in response to acetyl-
choline during coronary angiogra-
phy or by brachial artery flow-
mediated vasodilation (5,8). These
physiological tests are complex,
operator dependent, and provide
limited quantitative data (9,10).
Endothelium-derived micropar-
ticles (EMP) are small membrane-
shed vesicles generated from endo-
thelial cell surfaces in response
to cellular activation or injury/
apoptosis, and can potentially
reflect endothelial dysfunction
(11,12). Recently, we reported that
D144-EMP is derived selectively from human endothelial
ells (13) and that circulating plasma CD144-EMP levels
orrelate significantly with coronary endothelial dysfunction
nd are significantly elevated in patients with type 2 diabetes
nd atherosclerosis (13). Although EMP are still only used for
esearch purpose and in specialized laboratories because of their
Figure 1 Flow Diagram of Subject Recruitment
Thirty-one patients were excluded for the following reasons: malignant diseases (n
disease (n  3), and active infections (n  2). ACS  acute coronary syndromes;
Abbreviations
and Acronyms
ACS  acute coronary
syndromes
BNP  B-type natriuretic
peptide
CAD  coronary artery
disease
CHD  coronary heart
disease
CI  confidence interval
DM  diabetes mellitus
eGFR  estimated
glomerular filtration rate
EMP  endothelium-derived
microparticle(s)
HDL  high-density
lipoprotein
HR  hazard ratio
hsCRP  high-sensitivity
C-reactive protein
LDL  low-density
lipoproteinlusive nature and difficult assessment due to very small size
14), these findings underscore the potential application of
D144-EMP as a quantitative biomarker of endothelial
ysfunction.
We hypothesized that the addition of a quantitative
easure of endothelial dysfunction to a multiple biomarkers
trategy could improve the prediction of future cardiovas-
ular events. The hypothesis was tested by investigating the
tility of plasma CD144-EMP levels for prediction of
uture cardiovascular events in stable patients at high risk for
oronary heart disease (CHD), and examined the usefulness
f the modified multiple biomarkers strategy, including
ndothelial dysfunction assessed by EMP, to predict car-
iovascular complications.
ethods
tudy patients. In this prospective study, we screened 519
onsecutive Japanese patients between May 2003 and Au-
ust 2007 at Kumamoto University Hospital. Patients with
evere valvular heart disease requiring surgical intervention
ithin 1 month, scheduled for coronary revascularization,
ctive infection, or malignant disease were excluded from
he study (n  31). The 488 patients who fulfilled the study
riteria were divided into the following 4 groups: low-risk
atients who had no or 1 CHD risk factor, patients with
ultiple risk factors without documented coronary artery
isease (CAD), patients with documented CAD at stable
ondition (stable-CAD), and patients with acute coronary
yndromes (ACS) (Fig. 1). Stable-CAD represented pa-
ients with angiographically documented organic coronary
), unstable conditions (n  6), systemic inflammatory
coronary artery disease; CHD  coronary heart disease. 20
CAD 
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August 11, 2009:601–8 Multimarkers Strategy With Endothelial Injurytenosis of 50% by quantitative coronary angiography in
ajor coronary arteries. Risk factors for CHD were defined
s age 65 years (15); current smoking; family history of
schemic heart disease; hypertension (140/90 mm Hg or
aking antihypertensive medication) (16); dyslipidemia
high-density lipoprotein [HDL] cholesterol 40 mg/dl,
ow-density lipoprotein [LDL] cholesterol 140 mg/dl,
riglycerides 150 mg/dl, or receiving lipid-lowering treat-
ent); diabetes mellitus (DM) (17); body mass index25.0
g/m2 (16); hsCRP 2.0 mg/l; or chronic kidney disease
estimated glomerular filtration rate [eGFR] 60 ml/min/
.73 m2). The glomerular filtration rate was estimated using
he modified formula of Modification of Diet in Renal
isease study equation, which was proposed by the Japanese
ociety of Nephrology (18). This study protocol was con-
ucted in accordance with guidelines approved by the ethics
ommittee at our institution.
easurement of plasma levels of CD144-EMP and
lood parameters. Blood samples were withdrawn by ve-
ipuncture into vacutainer tubes containing sodium citrate
fter a 12-h overnight fast for stable patients and on
dmission to the emergency room for ACS patients, before
ny mechanical intervention. Fresh plasma was assayed
mmediately for CD144-EMP by flow cytometry using the
ethod described previously (13,14). We verified plasma
evels of CD144-EMP with standard plasma for each
ample. Standard plasma were subdivided into 1-use volume
nd stocked at80°C. One thawing of stock plasma did not
ffect CD144-EMP levels. We measured hsCRP by a
ephelometry with BN II (Siemens, Berlin, Germany) and
NP by a fluorescence enzyme immunoassay with AIA-21
Tosoh Bioscience, Tokyo, Japan). Total cholesterol, HDL
holesterol, triglyceride, LDL cholesterol, and creatinine
oncentrations were determined by routine laboratory
ethods.
tudy protocol. First, we compared plasma levels of
D144-EMP among low-risk patients (CHD risk factor
1), multiple risk patients (CHD risk factors 2), stable-
AD, and ACS patients. Second, patients with multiple
isk factors or stable-CAD were categorized as high-risk
atients for CHD and followed up every month at the
utpatient department until July 2008 or at end point (Fig.
). The end point was cardiovascular death, nonfatal myo-
ardial infarction, unstable angina, ischemic stroke, or
oronary revascularization to new lesions. Cardiovascular
vents were documented by phone calls to the patients or
heir families, followed by a review of medical records,
lectrocardiogram, ultrasound echocardiogram, and cardiac
nzyme data. Cardiovascular death was defined as death due
o myocardial infarction, congestive heart failure, or docu-
ented sudden cardiac death. Diagnosis of ischemic stroke
as made if the patient had clinical and radiological
vidence of stroke without intracranial hemorrhage. For
ubjects experiencing more than 2 acute events, only the first
vent was considered in the analysis. Revascularization
herapy based only on angiographic data, including percu- taneous coronary intervention-mediated restenosis, was not
ounted as a cardiovascular event. We used the previously
eported cutoff values of 52.6 pg/ml (19) and 2.0 mg/l (20),
nd the median levels for BNP, hsCRP, and CD144-EMP,
espectively, to divide our follow-up population into 2
roups: the high-level group and low-level group for the
articular parameter.
tatistical analysis. Results were expressed as mean  SD
r as frequencies (percentages), while BNP, hsCRP, and
D144-EMP levels were expressed as median and inter-
uartile range. The frequencies of risk factors and medica-
ions were compared between 2 groups by using chi-square
nalysis. Continuous variables were compared between 2
roups by the unpaired t test or Mann-Whitney U test, as
ppropriate. Data of the 4 groups were compared by 1-way
nalysis of variance, Kruskal-Wallis test, and chi-square
nalysis. Survival analysis was performed using the Kaplan-
eier method and assessed with the log-rank test.
The predictive value for cardiovascular events was as-
essed by Cox proportional hazards regression. The follow-
ng variables were incorporated first into the univariate
odel: age, sex, current smoking, hypertension, DM, body
ass index, HDL cholesterol, LDL cholesterol, eGFR,
NP, hsCRP, and CD144-EMP. Variables with p values
0.20 were then entered into a forward stepwise multivar-
ate Cox proportional hazards analysis. In this model, we
valuated the effect of the biomarkers, BNP, hsCRP, and
D144-EMP, according to quintile increment in biomar-
ers levels.
Proportional hazards assumption was confirmed by
choenfeld’s test. Estimates of the C statistic for Cox
roportional hazards regression models were calculated
21). The comparison of C statistics after the addition of the
iomarkers to the model with Framingham risk was esti-
ated (22). We also examined whether the addition of
arious combinations of biomarkers improved the discrim-
natory power of the model.
We assessed the calibration of Cox regression models by
he Grønnesby and Borgan (23) calibration test, which
ompares the number of events that are expected based on
stimation from 5 risk score groups. To evaluate whether
he global model fit improved after the addition of the
iomarkers, we performed likelihood ratio tests.
The statistical analyses were carried out using SPSS
ersion 15.0J for Windows (SPSS Inc., Chicago, Illinois),
TATA version 10.0 (StataCorp LP, College Station,
exas), and SAS version 9.1.3 (SAS Institute Inc., Cary,
orth Carolina). Statistical significance was defined as a
alue of p  0.05 from 2-sided tests.
esults
nrollment, classification, and follow-up of patients.
e screened 519 patients, but 31 patients were excluded
Fig. 1). Data of the remaining 488 patients were subjected
o analysis. In this study population, 387 patients at high
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Multimarkers Strategy With Endothelial Injury August 11, 2009:601–8isk for CHD were followed up, and the data of 378 patients
multiple risk factors, n  167; stable-CAD, n  220) were
vailable for analysis of cardiovascular events while 9 pa-
ients were lost to follow-up (Fig. 1). The follow-up period
as 1 to 62 months (mean 36 months).
omparison of CD144-EMP levels. All clinical factors
xcept the frequency of current smoking were significantly
ifferent among patients with various CHD risk. The
lasma levels of CD144-EMP increased significantly with
ncreased coronary risk factors and with complicated clinical
anifestations (patients at low-risk: n  51, median [inter-
uartile range], 0.303 [0.142 to 0.367]  106; multiple risk
actors: n  167, 0.508 [0.387 to 0.681]  106; stable-
AD: n  220, 0.604 [0.449 to 0.795]  106; ACS: n 
0, 0.983 [0.718 to 1.150]  106/ml, p  0.001) (Fig. 2).
DL cholesterol, eGFR, and hsCRP were higher in ACS
han stable-CAD (ACS vs. stable-CAD: LDL cholesterol:
21.2  30.0 mg/dl vs. 110.8  32.7 mg/dl, eGFR: 65.7 
0.8 ml/min/1.73 m2vs. 58.9  21.4 ml/min/1.73 m2, and
sCRP: 2.2 [0.7 to 7.8] mg/l vs. 1.2 [0.5 to 3.6] mg/l).
oreover, CD144-EMP levels were significantly higher in
CS patients than in stable-CAD patients (Fig. 2).
aseline clinical features of patients at high risk for
HD. Table 1 summarizes the baseline clinical features of
atients at high risk for CHD (multiple risk factors or
table-CAD; follow-up population). The mean age was
6.9 years and 61.4% were men. Plasma levels of CD144-
MP correlated weakly with hsCRP (r  0.16, p  0.002)
nd did not correlate with BNP (r  0.08, p  0.14).
ultivariate logistic regression analysis identified male sex
nd DM as significant risk factors of high EMP levels
above median) (men: hazard ratio [HR]: 1.685, 95%
Figure 2 Plasma Levels of CD144-EMP in
Patients With Various Cardiovascular Risks
The line within the box represents the median value; the top and bottom lines
of the box represent the 25th and 75th percentiles, respectively; and the top
and bottom vertical lines outside the boxes represent the 90th and 10th per-
centiles, respectively. ANOVA  analysis of variance; EMP  endothelium-
derived microparticle; other abbreviations as in Figure 1. Donfidence interval [CI]: 1.076 to 2.639, p  0.02; DM:
R: 1.551, 95% CI: 1.009 to 2.386, p  0.046).
ardiovascular events and biomarker levels. We re-
orded 55 cardiovascular events in patients at high risk for
HD during the follow-up period. Patients of the high
MP group developed significantly more cardiovascular
vents than the low EMP group during the follow-up
Table 2). Specifically, the incidences of cardiovascular
eath and ACS were significantly higher in the high-EMP
roup than in the low-EMP group (Table 2). Kaplan-Meier
nalysis based on high and low levels of biomarkers showed
significantly higher probability of cardiovascular events in
he presence of high levels of BNP, hsCRP, and EMP
uring the follow-up (log-rank test: BNP p  0.001,
sCRP p  0.001, and EMP p  0.001) (Figs. 3A to 3C).
ox proportional hazard analysis and C statistics for
ardiovascular events. Univariate and multivariate Cox
roportional hazards analysis for cardiovascular events
howed that age, BNP, hsCRP, and CD144-EMP were
ndependent predictors of future cardiovascular events in
aseline Clinical Characteristics of78 Follow-Up Patients at High Risk for CHDTable 1 Baseline Clinical Characteristics of378 Follow-Up Patients at High Risk for CHD
All Subjects (n  378)
Age, yrs 66.9  9.8
Sex, male/female (%/%) 232/146 (61.4/38.6)
Current smoking 68 (18.0)
Hypertension 279 (73.8)
Diabetes mellitus 157 (41.5)
Body mass index, kg/m2 23.7  3.4
HDL cholesterol, mg/dl 52.2  16.4
LDL cholesterol, mg/dl 114.4  31.4
eGFR, ml/min/1.73 m2 63.0  20.9
BNP, pg/ml 57.0 (22.7–156.3)
High-sensitivity CRP, mg/l 0.9 (0.4–2.4)
EMP,  106/ml 0.569 (0.427–0.761)
Medications
Antihypertensive drugs 338 (89.4)
Statins 174 (46.0)
ata are mean  SD, n (%), or median (interquartile range).
BNP  B-type natriuretic peptide; CHD  coronary heart disease; CRP  C-reactive protein;
GFR estimated glomerular filtration rate; EMP endothelium-derived microparticle; HDL
igh-density lipoprotein; LDL  low-density lipoprotein.
ardiovascular Events in Patientsith High or Low EMP LevelsTable 2 Cardiova cular Events in PatientsWith High or Low EMP Levels
High EMP
Group
(n  189)
Low EMP
Group
(n  189) p Value
Total cardiovascular events 41 14 0.001
Cardiovascular death 14 3 0.01
Acute coronary syndromes 12 3 0.03
Nonfatal myocardial infarction 4 0 0.12
Unstable angina 8 3 0.22
Ischemic stroke 5 5 1.00
Coronary revascularization to new lesions 10 3 0.09ata are number of patients.
EMP  endothelium-derived microparticle.
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August 11, 2009:601–8 Multimarkers Strategy With Endothelial Injuryatients at high risk for CHD (age: HR: 1.042, 95% CI:
.007 to 1.080, p  0.02; BNP: HR: 1.242, 95% CI: 1.004
o 1.536, p  0.046; hsCRP: HR: 1.468, 95% CI: 1.150 to
Figure 3 Kaplan-Meier Analysis for
the Probability of Cardiovascular Events
(A to C) Based on each cutoff point of B-type natriuretic peptide (BNP), high-
sensitivity C-reactive protein (hsCRP), and CD144 endothelium-derived micro-
particles (EMP). BNP 52.6 pg/ml, hsCRP 2.0 mg/l, and CD144-EMP 0.569 
106/ml.s.875, p  0.002; EMP: HR: 1.345, 95% CI: 1.094 to
.652, p  0.005) (Table 3). Framingham risk was not
ncorporated into multivariate analysis because it was con-
tructed by the same variables in univariate analysis. Fra-
ingham risk was confirmed to be a significant factor by
nivariate analysis in the present study (HR: 1.043, 95% CI:
.011 to 1.076, p  0.008). We then estimated the C
tatistic of Framingham risk alone. Separate incorporation
f each biomarker into the Framingham risk model showed
hat all biomarkers increased the C statistic for prediction of
ardiovascular events (C statistics: Framingham risk alone
.636, Framingham risk BNP 0.695, Framingham risk
sCRP 0.696, and Framingham risk  EMP 0.682) (Table 4).
oreover, we examined the additive usefulness of EMP in
ultiple biomarkers strategy based on Framingham risk and
NP, hsCRP, or both. EMP increased the C statistics in
ultiple biomarkers strategy (C statistics: Framingham
isk  BNP 0.695, Framingham risk  BNP  EMP
.741; Framingham risk  hsCRP 0.696, Framingham
isk  hsCRP  EMP 0.734; and Framingham risk 
NP  hsCRP 0.732, Framingham risk  BNP 
sCRP  EMP 0.763) (Table 4). The p value for the
choenfeld’s tests indicated that proportional hazards as-
umptions were appropriate (p  0.70). We also confirmed
ood calibration for the model in patients at high risk for
HD by Grønnesby and Borgan (23) statistics (p  0.34).
urthermore, models that included all biomarkers had better
lobal fit than models with only Framingham risk, as evaluated
y the likelihood ratio test (p  0.02).
We examined the effect modification of interaction
mong all biomarkers and found that there was an interac-
ion term between EMP and hsCRP (p  0.03).
iscussion
e demonstrated that circulating plasma levels of CD144-
MP in patients at high risk for CHD were independent
redictors of future cardiovascular events. We also found
hat the addition of multiple biomarkers, including endo-
helial dysfunction, as assessed by CD144-EMP, to the
ramingham risk model improved classification of risk, as
videnced by a substantial increase in the C statistics. Thus,
uantitative evaluation of cardiovascular risk leading to
therothrombogenic complications from multiple aspects
hat include endothelial dysfunction can be clinically useful
nd valuable in patients at high risk for CHD.
Although the mean age of the study population and
ombination of biomarkers were issues of concern in the
tudy design, the multiple biomarkers strategy, which is
ased on adding several biomarkers to the prediction model,
ncluding the established risk factors, is useful for risk
tratification of cardiovascular events (2,3). It has already
een demonstrated that BNP and hsCRP are independent
redictors in healthy subjects (24,25) and CHD patients
26,27), and are significant biomarkers that improve C
tatistics for death and cardiovascular events (2,3). Endo-
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Multimarkers Strategy With Endothelial Injury August 11, 2009:601–8helial dysfunction has also been recognized as an indepen-
ent predictor of future cardiovascular events (5–7). Despite
he pathophysiological significance of endothelial dysfunc-
ion in cardiovascular medicine, one cannot clinically assess
oronary endothelial dysfunction because the available
ethod is complex and invasive. It is probably for this
eason that endothelial dysfunction was not incorporated
nto the multiple biomarkers strategy. In addition to the use
f coronary reactivity to acetylcholine or brachial artery
ow-mediated vasodilation, endothelial dysfunction can be
ssessed by measuring circulating levels of intercellular
dhesion molecule 1, E-selectin (28), and von Willebrand
actor (29). Soluble biomarkers offer the advantage of
onvenience and quantitative assessment; however, there is
ittle evidence at present that such markers can accurately
redict future cardiovascular events. Because the aforemen-
ioned molecules can be produced from cells other than
ndothelial cells such as leukocytes (28) and platelets, we
eed to identify a highly specific soluble biomarker that
eflects endothelial dysfunction and can predict the progno-
is of CHD patients.
Microparticles are released from various circulating blood
ells and have many pathophysiological properties, as pro-
nivariate and Multivariate Cox Proportional Hazards Analysis for CTable 3 Univariate and Multivariate Cox Proportional Hazards A
Univariate
HR (95% CI)
Age, per yr 1.045 (1.010–1.080)
Sex (male) 1.498 (0.845–2.655)
Current smoking 0.886 (0.433–1.810)
Hypertension 0.808 (0.451–1.447)
Diabetes mellitus 1.967 (1.150–3.364)
Body mass index, per kg/m2 0.975 (0.904–1.052)
HDL cholesterol, per mg/dl 0.988 (0.971–1.006)
LDL cholesterol, per mg/dl 0.997 (0.989–1.006)
eGFR, per ml/min/1.73 m2 0.982 (0.969–0.995)
BNP, quintile increment 1.461 (1.190–1.792)
High-sensitivity CRP, quintile increment 1.693 (1.335–2.146)
EMP, quintile increment 1.469 (1.203–1.792)
I  confidence interval; HR  hazard ratio; other abbreviations as in Table 1.
Statistics for Cox Proportional Hazards Model toredict Cardi vascula Events in Follow-Up PatientsTable 4 C Statistics for Cox Proportional Hazards Model toPredict Cardiovascular Events in Follow-Up Patients
Risk Factors and Biomarkers C Statistic
Increment in
C Statistic
Framingham risk 0.636 0.046
Framingham risk  EMP 0.682
Framingham risk  BNP 0.695 0.046
Framingham risk  BNP  EMP 0.741
Framingham risk  hsCRP 0.696 0.038
Framingham risk  hsCRP  EMP 0.734
Framingham risk  BNP  hsCRP 0.732 0.031
Framingham risk  BNP  hsCRP  EMP 0.763m
iomarkers were incorporated as variables of 5 ingredients that were divided by quintiles.
hsCRP  high-sensitivity C-reactive protein; other abbreviations as in Table 1.oagulants and messengers (11). Microparticles detected by
D144 antigens (vascular endothelial cadherin), which are
ndothelial cell-type specific transmembrane adhesion mol-
cules located only on the endothelium, exist in human
lasma and are derived selectively from human endothelial
ells, and their plasma levels can be a clinically specific
arker for endothelial dysfunction (13,30). In the present
tudy, we used the CD144-EMP assay to quantitate endo-
helial dysfunction. Although the clinical significance of
easurement of microparticles has not been established yet,
s stated in the preceding text, the method used for
easurement of CD144-EMP is more specific, safe, simple,
nd rapid. Moreover, the fact that plasma levels of CD144-
MP independently predicted future cardiovascular events
n the present study indicates that measurement of plasma
D144-EMP levels could be potentially useful for risk
ssessment of endothelial dysfunction with potential cardio-
ascular complications.
Endothelial dysfunction is one component of vulnera-
le plaques and closely associated with the occurrence of
CS (31). Vulnerable plaques are characterized by a thin
brous cap with a large lipid core and superficial erosion
f the luminal endothelium. Severe endothelial dysfunc-
ion may predispose to vulnerable endothelium, and the
ain feature of endothelial vulnerability is probably
ndothelial erosion. A vulnerable endothelium can pro-
ote atherothrombogenic complications through endo-
helial erosion, but there are no reliable methods for
valuating the risk of endothelial vulnerability, including
ndothelial erosion (31,32). Therefore, cardiovascular
isk stratification that includes evaluation of endothelial
ysfunction is a sound approach. Analysis of the risk in
ifferent disease pathways is important, and we propose
hat evaluation of endothelial dysfunction could be an
mportant and clinically useful strategy. Based on the
oncept of vascular protection, a specific and quantifiable
vascular Events in Follow-Up Patientssis for Cardiovascular Events in Follow-Up Patients
is Multivariate Analysis
p Value HR (95% CI) p Value
0.01 1.042 (1.007–1.080) 0.02
0.17 Not selected —
0.74 Not selected —
0.47 0.616 (0.341–1.112) 0.11
0.01 1.597 (0.922–2.766) 0.10
0.52 Not selected —
0.19 Not selected —
0.53 Not selected —
0.006 Not selected —
0.001 1.242 (1.004–1.536) 0.046
0.001 1.468 (1.150–1.875) 0.002
0.001 1.345 (1.094–1.652) 0.005ardionaly
Analysarker that can monitor endothelial dysfunction is neces-
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ndothelial dysfunction.
A weak correlation between EMP and hsCRP resulted
n statistical modification of interaction between EMP
nd hsCRP. EMP levels correlated to some extent with
arious inflammatory markers, because inflammatory cy-
okines can induce the release of EMP, and the latter, in
urn, promote endothelial injury, leading to endothelial
ysfunction (11).
tudy limitations. One limitation of the present study is
he relatively small number of patients in a single center.
owever, this should result in underestimation, stressing
he need for further multicenter studies in a larger popula-
ion to confirm the present results. There is no consensus
bout measurement of EMP for assessment of endothelial
amage and prothrombotic state at this stage, and micro-
articles are still used only for research purposes. There is a
eed to standardize the EMP assay for the development and
stablishment of routine clinical tests, because measurement
f CD144-EMP could be potentially useful for the evalu-
tion of endothelial dysfunction. The number of this study
opulation was not estimated by power calculation. It is
ffective and necessary to have a plan for the number of
atients required for a prospective study.
onclusions
ndothelial dysfunction leading to cardiovascular com-
lications can be assessed quantitatively by measurement
f plasma levels of CD144-EMP. Moreover, a multiple
iomarkers strategy that includes endothelial dysfunction
ssessed by CD144-EMP can provide better risk strati-
cation of cardiovascular events and, hence, more thor-
ugh clinical assessment of patients who might benefit
rom more aggressive treatment strategies that improve
rognosis.
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